Abstract #0628

A New Biomarker for Neuroinflammation in Preclinical Alzheimer’s disease Progression

Yong Wang^1,2,3, Qing Wang^2,4, Joshua S Shimony², Anne M Fagan^4,5, John C Morris^5,6, and Tammie L.S. Benzinger^2,6,7

¹Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO, United States, ²Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States, ³Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States, ⁴Knight Alzheimer's Disease Research Center, St. Louis, MO, United States, ⁵Neurology, Washington University in St. Louis, St. Louis, MO, United States, ⁶Knight Alzheimer’s Disease Research Center, St. Louis, MO, United States, ⁷Neurosurgery, Washington University in St. Louis, St. Louis, MO, United States

The preclinical pathophysiology of Alzheimer’s disease (AD) is not limited to the neuronal compartments. Neuroinflammation characterized by activation of microglia and astrocytes may contribute as much to AD disease pathogenesis as do amyloid plaques and neurofibrillary tangles. We demonstrated that a novel magnetic resonance imaging technique, diffusion basis spectrum imaging (DBSI), can accurately image neuroinflammation changes that occur in preclinical AD patients. DBSI neuroinflammation biomarker can be used to identify asymptomatic subjects at highest risk of developing dementia, and lead to effective new AD disease-modifying therapies targeting neuroinflammation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here